Atara Biotherapeutics AI Stock Analysis
Want to see ATRA full AI Analyst Report?
Atara Biotherapeutics (ATRA) AI Stock Analysis
Atara Biotherapeutics
(NASDAQ:ATRA)
ATRA scores low primarily due to weak financials (steep revenue drop, very large losses, ongoing cash burn, and negative equity). Technicals also lean bearish with the stock below key moving averages and a negative MACD, while valuation provides limited support given losses (negative P/E) and no dividend yield.
Atara Biotherapeutics (ATRA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $78.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 36.32K
- Price to Earnings (P/E)
- -7.6
- Beta (1Y)
- 0.87
- Revenue Growth
- -97.39%
- EPS Growth
- -155.19%
- Country
- US
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Atara Biotherapeutics Business Overview & Revenue Model
Company Description
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments fo...
How the Company Makes Money
Atara Biotherapeutics primarily generates revenue through collaboration and license arrangements rather than recurring product sales (as a clinical-stage biotech, it generally does not have sustained commercial revenue). Key revenue streams include:...
Atara Biotherapeutics Financial Statement Overview
Summary
Financial performance is very weak: sharp TTM revenue decline (-35.99%), deeply negative profitability (net margin -533%), negative operating/free cash flow (-$13.0M), and negative equity (-$37.9M) that increases financing and dilution risk. Modest debt helps slightly, but does not offset the overall strain.
Income Statement
28NegativeBalance Sheet
22NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.96M | 120.77M | 128.94M | 8.57M | 63.57M | 20.34M |
| Gross Profit | 3.28M | 99.56M | 107.93M | -313.00K | -206.42M | -261.66M |
| EBITDA | -12.61M | 38.63M | -75.75M | -266.00M | -222.26M | -330.75M |
| Net Income | -14.61M | 32.69M | -85.40M | -276.13M | -228.30M | -340.14M |
Balance Sheet | ||||||
| Total Assets | 18.61M | 20.23M | 109.10M | 165.50M | 376.42M | 468.13M |
| Cash, Cash Equivalents and Short-Term Investments | 9.92M | 8.48M | 42.50M | 51.73M | 242.82M | 371.07M |
| Total Debt | 9.57M | 52.80M | 43.83M | 57.87M | 71.70M | 28.27M |
| Total Liabilities | 56.51M | 58.74M | 206.38M | 264.74M | 249.78M | 188.51M |
| Stockholders Equity | -37.90M | -38.50M | -97.28M | -99.23M | 126.64M | 279.61M |
Cash Flow | ||||||
| Free Cash Flow | -12.99M | -50.94M | -68.96M | -194.20M | -274.62M | -231.10M |
| Operating Cash Flow | -12.99M | -50.94M | -68.72M | -192.98M | -270.43M | -220.52M |
| Investing Cash Flow | 2.65M | 18.15M | 8.62M | 123.87M | 202.96M | 22.26M |
| Financing Cash Flow | 8.65M | 16.10M | 59.28M | 2.01M | 53.08M | 103.94M |
Atara Biotherapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Negative. The current price of 7.70 is below the 20-day moving average (MA) of 8.42, below the 50-day MA of 8.94, and below the 200-day MA of 7.83, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 38.45 is Neutral, neither overbought nor oversold. The STOCH value of 41.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATRA.
Atara Biotherapeutics Risk Analysis
Atara Biotherapeutics disclosed 76 risk factors in its most recent earnings report. Atara Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAtara Biotherapeutics Peers Comparison
Overall Rating
SRZN53Neutral
MGNX47Neutral
ZNTL44Neutral
ATRA42Neutral
TCRX38.35Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | $602.54M | -0.72 | 228.00% | ― | 192.12% | -100.54% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $140.60M | -2.72 | -142.22% | ― | -11.07% | 30.92% | |
| 44Neutral | $167.05M | -0.89 | -75.82% | ― | -100.00% | 7.45% | |
| 42Neutral | $78.45M | -7.62 | 38.79% | ― | -97.39% | -155.19% | |
| 38Underperform | $10.89M | -0.18 | -140.75% | ― | -38.43% | 20.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ATRA | Atara Biotherapeutics Inc | 7.70 | -5.40 | -41.22% | |
| MGNX | MacroGenics Inc | 2.20 | 0.69 | 45.70% | |
| ZNTL | Zentalis Pharmaceuticals Inc | 1.70 | 0.38 | 28.79% | |
| SRZN | Surrozen, Inc. | 31.61 | 18.81 | 146.95% | |
| TCRX | Tscan Therapeutics, Inc. | 0.16 | -0.81 | -83.51% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
